Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment.

Jensen SBK, Janus C, Lundgren JR, Juhl CR, Sandsdal RM, Olsen LM, Andresen A, Borg SA, Jacobsen IC, Finlayson G, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS

Nature communications15 Aug 2022Cited by 34 (Europe PMC)

PMID35970829PMCIDPMC9378667DOI10.1038/s41467-022-32307-yPepBankPUB-35970829

Download PDF PubMedAsk about this study

Jump to 4 results

Summary

Weight regain after weight loss remains a major challenge in obesity treatment and may involve alteration of eating and sedentary behavior after weight loss. In this randomized, controlled, double-blind trial, adults with obesity were randomized, in a 1:1:1:1 ratio stratified by sex and age group (<40 years and ≥40 years), to one-year weight loss maintenance with exercise, the GLP-1 receptor agonist liraglutide, or the combination, as compared with placebo, after low-calorie diet-induced weight loss. Primary outcome was change in body weight, which has been published. Here, we investigated the effects of weight loss maintenance with exercise, liraglutide, or the combination on weight loss-induced changes in the pre-specified explorative outcomes, eating and sedentary behavior in 130 participants who completed the trial according to the study protocol (exercise (n = 26), liraglutide (n = 36), combination (n = 29), and placebo (n = 39)). One year after weight loss, the placebo group had decreased postprandial appetite suppression score by 14%, and increased sedentary time by 31 min/day and regained weight. Liraglutide prevented the decrease in postprandial appetite suppression score compared with placebo (0% vs. -14%; P = 0.023) and maintained weight loss. Exercise after weight loss did not increase appetite or sedentary behavior compared with placebo, despite increased exercise energy expenditure and maintained weight loss. The combination of exercise and liraglutide increased cognitive restraint score (13% vs. -9%; P = 0.042), reflecting a conscious restriction of food intake, and decreased sedentary time by 41 min/day (-10 vs. 31 min/day; 95%CI, -82.3 to -0.2; P = 0.049) compared with placebo, which may have facilitated the additional weight loss. Targeting both eating and sedentary behavior could be the most effective for preventing weight regain.Trial registration: EudraCT number, 2015-005585-32; clinicaltrials.gov number, NCT04122716.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity after diet-induced weight loss, liraglutide prevented the decrease in postprandial appetite suppression score seen with placebo (0% vs -14%; P = 0.023).
In plain wordsIn adults with obesity after weight loss, liraglutide prevented the drop in appetite suppression after meals that happened with placebo.
Peptide
Liraglutide
Outcome
IncreasePostprandial appetite suppression score after weight loss
Study
n = 75
Comparator
Placebo
Analysis
Exploratory
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Postprandial appetite suppression score change
0%
liraglutide
Postprandial appetite suppression score change
−14%
placebo
Source sentences
Summary
Liraglutide prevented the decrease in postprandial appetite suppression score compared with placebo (0% vs. -14%; P = 0.023) and maintained weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, controlled, double-blind trial, adults with obesity were randomized, in a 1:1:1:1 ratio stratified by sex and age group (<40 years and ≥40 years), to one-year weight loss maintenance with exercise, the GLP-1 receptor agonist liraglutide, or the combination, as compared with placebo, after low-calorie diet-induced weight loss.
Show in the study text Report a problemFND-3597082901
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity after diet-induced weight loss, liraglutide maintained weight loss, whereas the placebo group regained weight.
In plain wordsIn adults with obesity after weight loss, people on liraglutide kept their weight loss, while people on placebo regained weight.
Peptide
Liraglutide
Outcome
DecreaseWeight loss maintenance
Study
n = 75
Comparator
Placebo
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
and maintained weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
and regained weight.
Summary · context
In this randomized, controlled, double-blind trial, adults with obesity were randomized, in a 1:1:1:1 ratio stratified by sex and age group (<40 years and ≥40 years), to one-year weight loss maintenance with exercise, the GLP-1 receptor agonist liraglutide, or the combination, as compared with placebo, after low-calorie diet-induced weight loss.
Show in the study text Report a problemFND-3597082902

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity after diet-induced weight loss, the combination of exercise and liraglutide increased the cognitive restraint score versus placebo (13% vs -9%; P = 0.042).
In plain wordsIn adults with obesity after weight loss, exercise plus liraglutide raised conscious food restriction more than placebo.
Peptide
Liraglutide
Outcome
IncreaseCognitive restraint score with exercise plus liraglutide
Study
n = 68
Comparator
Placebo
Analysis
Exploratory
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
Cognitive restraint score change
13%
exercise plus liraglutide
Cognitive restraint score change
−9%
placebo
Source sentences
Summary
The combination of exercise and liraglutide increased cognitive restraint score (13% vs. -9%; P = 0.042)
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, controlled, double-blind trial, adults with obesity were randomized, in a 1:1:1:1 ratio stratified by sex and age group (<40 years and ≥40 years), to one-year weight loss maintenance with exercise, the GLP-1 receptor agonist liraglutide, or the combination, as compared with placebo, after low-calorie diet-induced weight loss.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3597082903
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity after diet-induced weight loss, the combination of exercise and liraglutide decreased sedentary time versus placebo (-10 vs 31 min/day; P = 0.049).
In plain wordsIn adults with obesity after weight loss, exercise plus liraglutide reduced sitting time compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseSedentary time with exercise plus liraglutide
Study
n = 68
Comparator
Placebo
Analysis
Exploratory
Outcome group
Exercise and physical function · Whole body
Measurements
Sedentary time change
−10 min/day
exercise plus liraglutide
Sedentary time change
31 min/day
placebo
Source sentences
Summary
decreased sedentary time by 41 min/day (-10 vs. 31 min/day; 95%CI, -82.3 to -0.2; P = 0.049) compared with placebo, which may have facilitated the additional weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, controlled, double-blind trial, adults with obesity were randomized, in a 1:1:1:1 ratio stratified by sex and age group (<40 years and ≥40 years), to one-year weight loss maintenance with exercise, the GLP-1 receptor agonist liraglutide, or the combination, as compared with placebo, after low-calorie diet-induced weight loss.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3597082904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT05574439

Young Adults With Early-onset Obesity Treated With Semaglutide

Signe Torekovn = 24630 May 2022 to 1 Apr 2026

Obesity, Adolescent

Trial page ClinicalTrials.govUpdated 8 Jul 2026

Status unknownPhase 4NCT04122716

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet

Signe Torekovn = 215Sept 2016 to est. Nov 2021

Obesity

Trial page ClinicalTrials.govUpdated 2 Nov 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.